VERTEX PHARMACEUTICALS INC / MA Proceeds from (Repayments of) Secured Debt
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Proceeds from (Repayments of) Secured Debt of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfSecuredDebt · last filed 2016-02-16
- VERTEX PHARMACEUTICALS INC / MA proceeds from (repayments of) secured debt for the quarter ending 2015-12-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA proceeds from (repayments of) secured debt for the quarter ending 2014-12-31 was -$140.00K.
- VERTEX PHARMACEUTICALS INC / MA proceeds from (repayments of) secured debt for the quarter ending 2013-12-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA proceeds from (repayments of) secured debt for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- VERTEX PHARMACEUTICALS INC / MA proceeds from (repayments of) secured debt for fiscal 2014 was $294.24M.
- VERTEX PHARMACEUTICALS INC / MA proceeds from (repayments of) secured debt for fiscal 2013 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA proceeds from (repayments of) secured debt for fiscal 2012 was $0.00.
| Period end | Proceeds from (Repayments of) Secured Debt 3 month | Proceeds from (Repayments of) Secured Debt 9 month | Proceeds from (Repayments of) Secured Debt 12 month |
|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $0.00 10-K · filed 2016-02-16 | |
| 2015-09-30 | $0.00 10-Q · filed 2015-10-30 | ||
| 2014-12-31 | -$140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $294.24M 10-K · filed 2016-02-16 | |
| 2014-09-30 | $294.38M 10-Q · filed 2015-10-30 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $0.00 10-K · filed 2016-02-16 | |
| 2013-09-30 | $0.00 10-Q · filed 2014-11-06 | ||
| 2012-12-31 | $0.00 10-K · filed 2015-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |